Trupanion (NASDAQ:TRUP – Get Free Report) had its price target raised by equities research analysts at Stifel Nicolaus from $28.00 to $29.00 in a report issued on Thursday,Benzinga reports. The firm currently has a “hold” rating on the financial services provider’s stock. Stifel Nicolaus’ price objective would suggest a potential downside of 6.75% from the stock’s current price.
Several other research analysts also recently issued reports on TRUP. Atlantic Securities set a $42.00 target price on shares of Trupanion in a research note on Wednesday, July 15th. Weiss Ratings upgraded shares of Trupanion from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 12th. Finally, Zacks Research raised Trupanion from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, Trupanion presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.80.
Read Our Latest Stock Analysis on Trupanion
Trupanion Stock Performance
Trupanion (NASDAQ:TRUP – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The financial services provider reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.05. The firm had revenue of $392.93 million during the quarter, compared to the consensus estimate of $389.72 million. Trupanion had a return on equity of 5.96% and a net margin of 1.53%.The company’s revenue was up 11.1% on a year-over-year basis. During the same period last year, the company earned $0.22 earnings per share. On average, equities analysts expect that Trupanion will post 0.61 EPS for the current fiscal year.
Insider Buying and Selling
In related news, COO John R. Gallagher sold 3,603 shares of the stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $21.69, for a total value of $78,149.07. Following the completion of the sale, the chief operating officer directly owned 33,065 shares of the company’s stock, valued at approximately $717,179.85. This represents a 9.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Fawwad Qureshi sold 6,177 shares of Trupanion stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $22.18, for a total transaction of $137,005.86. Following the transaction, the chief financial officer directly owned 2,081 shares in the company, valued at $46,156.58. This represents a 74.80% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 18,785 shares of company stock valued at $422,862. Insiders own 5.58% of the company’s stock.
Institutional Investors Weigh In On Trupanion
Institutional investors and hedge funds have recently bought and sold shares of the business. Susquehanna Fundamental Investments LLC purchased a new position in shares of Trupanion in the second quarter valued at about $1,679,000. Bank of America Corp DE purchased a new stake in shares of Trupanion during the second quarter worth about $14,262,000. Jupiter Topco LLC purchased a new stake in shares of Trupanion during the second quarter worth about $370,000. PDT Partners LLC bought a new stake in Trupanion during the 2nd quarter valued at approximately $1,044,000. Finally, Canada Pension Plan Investment Board bought a new stake in Trupanion during the 2nd quarter valued at approximately $263,000.
Trupanion Company Profile
Trupanion, Inc is a pet medical insurance company that provides comprehensive insurance coverage for cats and dogs. The company’s core offering is a single, customizable medical policy designed to cover veterinary diagnostic tests, surgeries, hospital stays and congenital or hereditary conditions. Trupanion seeks to streamline the claims process by offering direct payment options to participating veterinarians, reducing the need for upfront payments by pet owners.
Founded in 1999 by Darryl Rawlings and headquartered in Seattle, Washington, Trupanion began operations in the early 2000s and has grown its presence through both digital channels and partnerships with veterinary hospitals.
Further Reading
- Five stocks we like better than Trupanion
- Nasdaq’s 23-Hour Trading Push Could Turn Global Liquidity Into a Growth Engine
- Diamondback Hits a Milestone at Just the Right Time
- Analog Devices’ AI Pivot Could Push Shares to Fresh Highs
- One Platform, Every Ailment: Hinge Health’s Gamble
Receive News & Ratings for Trupanion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trupanion and related companies with MarketBeat.com's FREE daily email newsletter.
